Iterum Therapeutics reports Q4 non-GAAP EPS (12c) vs. (81c) last year

“While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAH is made available to patients as soon as possible to address the substantial unmet need for effective treatment options for uncomplicated urinary tract infections,” said Corey Fishman, CEO. “ORLYNVAH will potentially be the first branded uUTI product to enter the U.S. market in over 25 years and the first and only oral penem approved for use in the U.S.”